Peer-reviewedCC BYJournal for ImmunoTherapy of Cancer6 Nov 2026

270 AgenT-797, an allogeneic iNKT cell therapy, enables tumor-cell killing in a human organoid model of immune checkpoint inhibitor–refractory colorectal cancer liver metastases

Nils-Petter Rudqvist¹
Bishnu Joshi²
Dhan Chand³
Benjamin Morin⁴
Reed Masakayan⁵
Shanmugarajan Krishnan⁶
Olivier Le Tonqueze⁷
Robert B Stein⁸
Justin G Keith⁹
Nick Kushner⁷
John Chamberland⁹

9 affiliations

¹7Agenus, Boston, MA, USA
²1 Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA
³9 Agenus Inc, Lexington, Massachusetts, USA
⁴1Agenus Inc., Lexington, MA, USA
⁵1MiNK Therapeutics, Lexington, MA, USA
⁶2Agenus, Lexington, MA, USA
⁷MiNK Therapeutics, Lexington, MA, USA
⁸Isosceles Pharmaceuticals, Wilmington, NC, USA
⁹Agenus Inc., Lexington, MA, USA

Open at source PDF DOI Cite

611 Imneskibart + low-dose subcutaneous IL-2 ± nivolumab in doublet checkpoint inhibitor-refractory melanoma: promising activity in an ongoing phase 1/2 study
Andrew Haydon, Jose Lutzky, Siwen Hu-Lieskovan +17
Journal for ImmunoTherapy of Cancer7 Nov 2026Peer-reviewedCC BYFull textOncologyDOAJ
Corticosteroid-refractory checkpoint inhibitor pneumonitis in lung cancer: biological heterogeneity and mechanism-informed management
Rong Zhang, Xiaoxue Zhang, Xiulan He +1
Frontiers in Immunology28 Oct 2026Peer-reviewedCC BY 4.0OncologyCrossref
FOLFOX-HAIC plus regorafenib for the treatment of unresectable colorectal liver metastases refractory to first and second-line systemic chemotherapy
Jiacheng Liu, Songlin Song, Wei Yao +4
BMC Cancer1 Jul 2026Peer-reviewedCC BYFull textOncologyDOAJ
Extracorporeal photopheresis for the treatment of steroid-refractory immune related adverse events from immune checkpoint inhibitor therapy: a multi-center phase Ib/II clinical trial
Roxane Riemer, Lukas M. Braun, Sophie Giesler +43
Nature Communications23 Oct 2026Peer-reviewedCC BY 4.0Full textOncologyCrossrefEurope PMC
Multimodal Immune Profile Score (IPS) as a Pan-Cancer Biomarker for Stratifying Outcomes of Immune Checkpoint Inhibitor Benefit in Microsatellite Stable Colorectal Cancer and Rare Solid Tumors
M. A. Ting-Lin, E. S. Antonarakis, X. Wang +23
medRxiv7 Oct 2026PreprintPublic domainFull textOncologymedRxiv

Cite

BibTeX RIS

BibTeX

@article{rudqvist2026agent797,
  title = {{270 AgenT-797, an allogeneic iNKT cell therapy, enables tumor-cell killing in a human organoid model of immune checkpoint inhibitor–refractory colorectal cancer liver metastases}},
  author = {Nils-Petter Rudqvist and Bishnu Joshi and Dhan Chand and Benjamin Morin and Reed Masakayan and Shanmugarajan Krishnan and Olivier Le Tonqueze and Robert B Stein and Justin G Keith and Nick Kushner and John Chamberland},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2026},
  month = nov,
  doi = {10.1136/jitc-2026-sitc2026.0270},
  url = {https://doi.org/10.1136/jitc-2026-sitc2026.0270},
  note = {CC BY},
}

RIS

TY  - JOUR
TI  - 270 AgenT-797, an allogeneic iNKT cell therapy, enables tumor-cell killing in a human organoid model of immune checkpoint inhibitor–refractory colorectal cancer liver metastases
AU  - Nils-Petter Rudqvist
AU  - Bishnu Joshi
AU  - Dhan Chand
AU  - Benjamin Morin
AU  - Reed Masakayan
AU  - Shanmugarajan Krishnan
AU  - Olivier Le Tonqueze
AU  - Robert B Stein
AU  - Justin G Keith
AU  - Nick Kushner
AU  - John Chamberland
PY  - 2026
DA  - 2026/11/06
JO  - Journal for ImmunoTherapy of Cancer
DO  - 10.1136/jitc-2026-sitc2026.0270
UR  - https://doi.org/10.1136/jitc-2026-sitc2026.0270
SN  - 2051-1426
ER  -

Related

Cite